• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Dermatology biotech Dermata Therapeutics sets terms for $15 million IPO

firstwordpharmaJuly 05, 2021

Tag: dermatology , IPO , DMT310

Dermata Therapeutics plans to raise $15 million in its initial public offering of 1.9 million shares at a price range of $7 to $9, Renaissance Capital reported.

Dermata’s lead candidate, DMT310, is a once-weekly topical product currently under clinical development for acne, psoriasis, and rosacea. 

The company recently received results from a Phase IIb trial of DMT310 for the treatment of moderate-to-severe acne. It plans to initiate two pivotal Phase III trials in the second half of 2022.


Previous:Large-scale drug analysis reveals potential new COVID-19 antivirals

Next:Brazil top court gives nod for probe into Bolsonaro over vaccine deal

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Dermatology biotech Dermata Therapeutics sets terms for $15 million IPO | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

liposome

liposome
Triporelin

Triporelin
Teniposide

Teniposide
A-Lipoic-Acid

A-Lipoic-Acid
 Alpha Lipoic Acid

 Alpha Lipoic Acid
4'-Demethylepipodophyllotoxin

4'-Demethylepipodophyllotoxin
Sodium Tripolyphosphate

Sodium Tripolyphosphate
Calcipotriene

Calcipotriene
high quality Glycyrrhizinate dipotassium from GMP factory in China

high quality Glycyrrhizinate dipotassium from GMP factory in China
Siponimod

Siponimod

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service